Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
29.42
-0.24 (-0.81%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Today 17:04 EDT
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Via
Benzinga
3 Dirt Cheap Stocks to Buy Right Now
September 21, 2024
Bargain hunters should love these great stocks.
Via
The Motley Fool
Pfizer Advances On Its Cancer Journey
September 20, 2024
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024...
Via
Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
September 20, 2024
Via
Benzinga
Current Report: Pfizer (PFE)
September 19, 2024
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer's share price fell about 12.7% from $34.07 to $29.75 as of Wednesday’s...
Via
Talk Markets
Pfizer Unusual Options Activity
September 17, 2024
Via
Benzinga
Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
September 16, 2024
Via
Benzinga
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
September 15, 2024
Pfizer's sky-high dividend yield is tempting, but is it sustainable?
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 18, 2024
Via
Benzinga
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
September 18, 2024
Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity Residential. Moderna has been disappointing, but Cramer likes Vertiv and...
Via
Benzinga
3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever
September 18, 2024
After underperforming over the past few years, these stocks offer huge dividend yields that could keep rising throughout your retirement.
Via
The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
September 18, 2024
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Via
The Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
Telemedicine once seemed like it was going to revolutionize healthcare.
Via
The Motley Fool
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
September 17, 2024
The September syndrome is already visible in U.S. stock markets. At this stage, investment in stocks with high dividend yield strong price appreciation potential in the short term should enhance...
Via
Talk Markets
Intel, Microsoft, Meta Platforms, Pfizer, Tesla: Why These 5 Stocks Are On Investors' Radars Today
September 16, 2024
On Monday, major U.S. indices showed mixed results. The Dow Jones Industrial Average closed 0.5% higher at 41,622.08
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
September 16, 2024
The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.
Via
The Motley Fool
Topics
Supply Chain
Exposures
Supply Chain
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
September 16, 2024
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and...
Via
Benzinga
Exposures
COVID-19
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
September 13, 2024
The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday.
Via
Investor's Business Daily
Got $5,000? 3 Dirt Cheap Stocks to Buy Right Now
September 13, 2024
These stocks all trade at less than 14 times their expected future profits.
Via
The Motley Fool
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
The biotech continues to earn important wins, but is it enough?
Via
The Motley Fool
A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
September 13, 2024
These players have had their ups and downs -- but the future looks bright.
Via
The Motley Fool
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
September 11, 2024
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.
Via
Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
September 11, 2024
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...
Via
Benzinga
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.
Via
The Motley Fool
Exposures
COVID-19
2 Beaten-Down Stocks That Could Be Great Buys on the Dip
September 11, 2024
They're down but not out, at least not yet.
Via
The Motley Fool
3 High-Yield Stocks to Buy Hand Over Fist in September
September 10, 2024
The time is right to buy all three of these high-yield dividend stocks.
Via
The Motley Fool
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...
Via
Benzinga
Why Is Moderna Stock Trading Higher On Monday?
September 09, 2024
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu...
Via
Benzinga
Exposures
COVID-19
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
September 09, 2024
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics,...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.